SCHEMBL1703317

SCHEMBL1703317

c1csc(C2(N3CCC3)CCC3(CC2)OCCO3)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.63
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
PRCP P42785 1/20 0.63
SLC6A9 P48067 4/20 0.40
HSD17B10 Q99714 1/20 0.39
CYP2C19 P33261 2/20 0.37
CYP2C9 P11712 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SLC6A2 P23975 1/20 0.36
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
SLC6A3 Q01959 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7695403 0.79 SIGMAR1 (0.77) SIGMAR1MEN1KMT2APRCPSLC6A9
SCHEMBL1742361 0.78 SIGMAR1 (1.00) SIGMAR1MEN1KMT2APRCPSLC6A9
Tenocyclidine SCHEMBL517558 0.78 SIGMAR1 (1.00) SIGMAR1MEN1KMT2APRCPSLC6A9
Tenocyclidine SCHEMBL7204633 0.76 SIGMAR1 (0.97) SIGMAR1MEN1KMT2APRCPSLC6A9
SCHEMBL1702895 0.76 SIGMAR1 (0.67) SIGMAR1MEN1KMT2APRCPSLC6A9
SCHEMBL733824 0.75 SIGMAR1 (0.59) SIGMAR1MEN1KMT2APRCPSLC6A9
SCHEMBL7701615 0.74 SIGMAR1 (0.79) SIGMAR1MEN1KMT2APRCPSLC6A9
SCHEMBL17438697 0.73 MEN1 (0.58) SIGMAR1MEN1KMT2APRCPSLC6A9
SCHEMBL20887823 0.73 OPRM1 (0.47) SIGMAR1MEN1KMT2APRCPCYP2C19
SCHEMBL2200621 0.72 SIGMAR1 (0.64) SIGMAR1PRCPSLC6A9KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121691-B1 SPIROCYCLIC CYCLOHEXANE DERIVATIVES GRUENENTHAL GMBH (DE) 2012-04-18 EP disclosed
US-7960404-B2 Spirocyclic cyclohexane compounds GRUENENTHAL GMBH (DE) 2011-06-14 US disclosed
US-20100048553-A1 Spirocyclic Cyclohexane Compounds GRUENENTHAL GMBH (DE) 2010-02-25 US disclosed
EP-2121691-A1 SPIROCYCLIC CYCLOHEXANE DERIVATIVES Grünenthal GmbH (DE) 2009-11-25 EP disclosed
WO-2008101660-A1 SPIROCYCLIC CYCLOHEXANE DERIVATIVES Grünenthal GmbH (DE) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048553-A1 Spirocyclic Cyclohexane Compounds PKD2, PKD1, RYR1 SIGMAR1 220/4885MEN1 1654/4885KMT2A 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.